首页 | 本学科首页   官方微博 | 高级检索  
     


Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
Authors:Francesco Angotzi  Andrea Visentin  Federico Scarmozzino  Alessandro Cellini  Roberta Bertorelle  Marco Pizzi  Gianni Binotto  Angelo Paolo Dei Tos  Livio Trentin
Affiliation:1.Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, 35128 Padova, Italy; (F.A.); (A.V.); (A.C.); (G.B.);2.Surgical Pathology and Cytopathology Units, Department of Medicine, University of Padova, 35100 Padova, Italy; (F.S.); (M.P.); (A.P.D.T.);3.Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, 35128 Padova, Italy;
Abstract:The disease course of chronic lymphocytic leukemia (CLL) is frequently characterized by the occurrence of various complications, such as second primary cancer, which can impact patients’ prognoses. While therapies for CLL have evolved tremendously in the past decades, overlooking the possibility of rare neoplasms that arise along with CLL may hinder the benefit that these therapies grant to patients. Moreover, the ability of newer therapies to alter the landscape of these complications is still largely unknown. Primary myelofibrosis (PMF) is not commonly associated with CLL, with only a few cases reported in the literature, with little information regarding the clinico-biological features and the optimal management for these associated conditions. Here, we report two unusual cases of PMF that occurred a few months after the start of therapy for CLL with targeted agents (ibrutinib and venetoclax). Both cases represented a diagnostic and therapeutic challenge, underscoring the need for clinicians to remain vigilant about the possible co-occurrence of these two hematological malignancies, especially in the era of targeted therapy for CLL.
Keywords:chronic lymphocytic leukemia   primary myelofibrosis   ibrutinib   venetoclax
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号